Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

21. Methylphenidate

Methylphenidate USE OF METHYLPHENIDATE IN PREGNANCY 0344 892 0909 USE OF METHYLPHENIDATE IN PREGNANCY (Date of issue: January 2018 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Methylphenidate is a central nervous system stimulant (...) used in the management of attention deficit hyperactivity disorder (ADHD). It is also used off-license in the treatment of narcolepsy. The data regarding therapeutic use of methylphenidate do not suggest a significant increase in overall congenital or cardiac malformation rates, although a single study found an increased risk of conotruncal and major arch anomalies following exposure in utero. Increased risks of spontaneous abortion with methylphenidate use in early pregnancy and low Apgar score

2014 UK Teratology Information Service

22. Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy

Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Punja S, Zorzela L, Hartling L, Urichuk L, Vohra S CRD summary This review concluded that long-acting (...) methylphenidate had a modest benefit, over short-acting methylphenidate, for attention or overactivity, and hyperactivity or impulsivity, reported by parents, but short-acting methylphenidate was better, for hyperactivity reported by teachers. Discrepancies in ratings, possible overestimated effect sizes, small samples, and no long-term data, mean that these conclusions may not be reliable. Authors' objectives To assess the efficacy and safety of short-acting versus long-acting methylphenidate, to manage

Full Text available with Trip Pro

2013 DARE.

23. Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability

Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Article Text Children & Adolescents Methylphenidate reduces ADHD symptoms in children with severe ADHD

2013 Evidence-Based Mental Health

24. Quillivant XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension

Quillivant XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension Drug Approval Package: QUILLIVANT XR (methylphenidate) NDA #202100 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - QUILLIVANT XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension 25 mg per 5 mL Company: NextWave Pharmaceuticals, Inc. Application No.: 202100 Approval Date: 09/27/2012 Persons with disabilities having problems accessing the PDF files below

2012 FDA - Drug Approval Package

25. Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD

Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Article Text Therapeutics Review

2012 Evidence-Based Mental Health

26. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review]

[Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Jang BH, Lee HY, Jung YJ, An JH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Jang BH, Lee HY, Jung YJ, An JH. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-C-12-007. 2012 Authors' conclusions The research was carried out using the basic existing systematic review framework suggested by the Agency for Healthcare Research and Quality (AHRQ 2009

2012 Health Technology Assessment (HTA) Database.

27. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

28. OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD

OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD | Therapeutics Initiative Independent Healthcare Evidence > > OROS methylphenidate (Concerta) for the treatment of children and adults with ADHD Introduction Pharmaceutical Services Division (PSD) requested an update to the 2006 Therapeutics Initiative review of Concerta (OROS MPH) for the treatment of children and adults with ADHD (...) . The 2006 report included a systematic review in children and adolescents with ADHD. The recent submission includes additional new information in children and adolescents and also an additional new indication, for the treatment of adult patients with ADHD. Drug OROS methylphenidate is a central nervous system stimulant and a controlled substance under Schedule II. The OROS delivery technology provides a mixture of immediate and delayed release. Within 1 hour, plasma MPH concentrations reach an initial

2010 Therapeutics Letter

29. Methylphenidate: new patient information

Methylphenidate: new patient information Methylphenidate: new patient information - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Methylphenidate: new patient information The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers Published 11 December 2014 From: Therapeutic area: , Contents Article date: January 2010 Methylphenidate is a stimulant treatment (...) for children aged 6 years or older and adolescents with attention-deficit hyperactivity disorder (ADHD). Patient information The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers. This includes a tear-off section for children and adolescents who are taking methylphenidate. This tear-off section includes the most important messages written in an engaging style for children

2010 MHRA Drug Safety Update

30. Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial (PubMed)

Side effects of methylphenidate in childhood cancer survivors: a randomized placebo-controlled trial To investigate the frequency and severity of side effects of methylphenidate among childhood survivors of acute lymphoblastic leukemia and brain tumors and identify predictors of higher adverse effect levels.Childhood cancer survivors (N = 103) identified as having attention and learning problems completed a randomized, double-blind, 3-week, home-crossover trial of placebo, low-dose (...) methylphenidate (0.3 mg/kg; 10 mg twice daily maximum) and moderate-dose methylphenidate (0.6 mg/kg; 20 mg twice daily maximum). Caregivers completed the Barkley Side Effects Rating Scale (SERS) at baseline and each week during the medication trial. Siblings of cancer survivors (N = 49) were recruited as a healthy comparison group.There was a significantly higher number and severity of symptoms endorsed on the SERS when patients were taking moderate dose compared with placebo or low dose, but not low dose

Full Text available with Trip Pro

2009 EvidenceUpdates

31. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate

Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate Lan Y, Zhang LL, Luo R CRD summary This review identified trials of traditional Chinese medicine compared (...) with methylphenidate in children with attention deficit and hyperactivity disorder. The authors concluded that traditional Chinese medicine may be equal or superior to methylphenidate, but that more research was needed. Several methodological problems with the review may mean that the authors’ conclusions are not reliable. Authors' objectives To summarise existing evidence on the comparative effects of traditional Chinese medicine and methylphenidate for treating children with attention deficit and hyperactivity

2009 DARE.

32. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain Hong J, Dilla T, Arellano (...) J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to evaluate the cost-effectiveness of atomoxetine compared with methylphenidate (immediate and extended release) or no treatment, in Spanish children with attention

Full Text available with Trip Pro

2009 NHS Economic Evaluation Database.

33. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults

Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults Hardy SE CRD summary The review did not find definitive evidence (...) of effectiveness of methylphenidate in medically ill older adults with depression, fatigue or apathy, although it appeared to be tolerated in the short term. Due to variation in outcomes, methodological flaws in the included studies and shortcomings in the review process, the reliability of the author's conclusions is not clear. Authors' objectives To assess the efficacy and tolerability of methylphenidate for the treatment of depressive symptoms, fatigue and apathy in medically ill older adults and adults

Full Text available with Trip Pro

2009 DARE.

34. Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD

Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Osmotically released methylphenidate is more effective than atomoxetine in children and adolescents with ADHD Article Text Therapeutics Osmotically released

2009 Evidence-Based Mental Health

35. Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms

Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Methylphenidate and psychosocial treatments either alone or in combination reduce ADHD symptoms Article Text Therapeutics Review: Methylphenidate and psychosocial

2009 Evidence-Based Mental Health

36. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder

Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

37. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder (PubMed)

Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder Children with attention-deficit/hyperactivity disorder often have varying needs for coverage of their symptoms throughout the day. The objectives of this study were to determine the efficacy, duration of action, and safety of methylphenidate transdermal system worn for variable times by children (ages 6-12) diagnosed with ADHD.Methylphenidate dose was optimized over 5 weeks

2008 EvidenceUpdates

38. Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response (PubMed)

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD).In a large placebo-controlled, double-blind study, patients ages 6-16 (...) with ADHD, any subtype, were randomly assigned to receive 0.8-1.8 mg/kg per day of atomoxetine (N=222), 18-54 mg/day of osmotically released methylphenidate (N=220), or placebo (N=74) for 6 weeks. The a priori specified primary analysis compared response (at least 40% decrease in ADHD Rating Scale total score) to osmotically released methylphenidate with response to atomoxetine and placebo. After 6 weeks, patients treated with methylphenidate were switched to atomoxetine under double-blind

2008 EvidenceUpdates

39. Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD

Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD Article Text

2008 Evidence-Based Mental Health

40. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management.

Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures

2008 American Association of Poison Control Centers